Species |
SARS-CoV-2 |
Protein Construction |
S1 protein (Gln14-Arg685) Accession # P0DTC2 |
Poly-His |
N-term |
C-term |
|
Purity |
> 90% as analyzed by SDS-PAGE |
Endotoxin Level |
< 0.2 EU/μg of protein by gel clotting method |
Biological Activity |
SARS-CoV-2 Spike protein (S1, D614G, His Tag) can bind with human ACE2 (Cat.No.: Z03484) in functional ELISA assay. |
Expression System |
293 Cells |
Theoretical Molecular Weight |
79 kDa |
Formulation |
Supplied as a solution in PBS pH 7.2. |
Concentration |
Please refer to the COA for the specific lot. |
Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at -20°C or below. Avoid repeated freeze-thaw cycles. |
Immobilized ACE-2 Fc Chimera, Human (Cat. No. Z03484) at 2 μg/mL can bind SARS-CoV-2 Spike protein (S1, D614G, His Tag) (Cat. No. Z03507) with a serial dilution.
THETM His Tag Antibody [HRP], mAb, Mouse (Cat.No.A00612) is used as a secondary antibody (0.1 μg/mL).
Lane 1: 1μg of SARS-CoV-2 Spike protein (S1, D614G, His Tag), reducing(R)
> 95% as analyzed by SDS-PAGE
Target Background |
SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. The spike protein mutation D614G became dominant during the globally pandemic. The D614G mutation enhances its replication ability in upper respiratory tract, transmission ability and viral loads in the patients’ lung epithelial cells. It may also affect vaccine efficacy and antibody therapy. |
Synonyms |
SARS-CoV-2 S1 protein, D614G; 2019-nCoV S1 protein, D614G |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.